A Stage 1 Prospective Randomized Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor [A1PI] Augmentation Therapy in Subjects with A1PI Deficiency and Chronic Obstructive Pulmonary Disease [COPD]
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to understand whether you can take the approved doses as well as higher doses of ARALAST NP or GLASSIA without problems and whether the prescribed dose of the study drugs can slow down the changes in the lungs over time that are seen in people with Alpa1-Proteinase Inhibitor [A1PI] deficiency and Chronic Obstructive Pulmonary Disease [COPD].
Description
The purpose of this study is to understand whether you can take the approved doses as well as higher doses of ARALAST NP or GLASSIA without problems and whether the prescribed dose of the study drugs can slow down the changes in the lungs over time that are seen in people with Alpa1-Proteinase Inhibitor [A1PI] deficiency and Chronic Obstructive Pulmonary Disease [COPD].
Details
| Condition | Chronic Obstructive Pulmonary Disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX6746 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.